Abstract: A medicinal nanocomposite is provided. The medicinal nanocomposite includes 80 to 99 wt. % carrier particles of a porous silicate material selected from a group including mesoporous silica, silicalite, mesosilicalite, silver-incorporated silicalite, and silver- incorporated mesosilicalite, the carrier particles comprising a pore framework, 0.5 to 10 wt. % silver nanoparticles (Ag NPs) disposed on the pore framework, and 0.5 to 10 wt. % of a platinum-containing pharmaceutical compound disposed on at least one surface selected from an interior pore surface of the carrier particles, an exterior surface of the carrier particles, and a surface of the silver nanoparticles. The medicinal nanocomposite releases less than 10 mole % of the platinum-containing pharmaceutical compound after 60 to 84 hours at a pH of 4.5 to 7, based on an initial amount of the platinum-containing pharmaceutical compound present in the medicinal nanocomposite.

Abstract: Long term storage stable bendamustine-containing compositions are disclosed. The compositions can include bendamustine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable fluid which can include in some embodiments PEG, PG or mixtures thereof and an antioxidant or chloride ion source. The bendamustine-containing compositions have less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 223 nm, after at least about 15 months of storage at a temperature of from about 5° C. to about 25° C.

Abstract: The present specification discloses solid solution pharmaceutical compositions comprising hard fats, liquid lipids, and one or more cannabidiols, including a phytocannabinoid, an endocannabinoid, a synthetic cannabinoid, or a combination thereof, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.

Abstract: Provided herein are methods of treatment, compositions, systems and kits using polymer particles as restraints of neutrophil function. Such methods include, but are not limited to, methods of preventing, treating, and/or ameliorating inflammatory diseases, infections, autoimmune diseases, malignant diseases, and other diseases or conditions in which neutrophils may be implicated. In some embodiments, polymer particles are useful for diagnosing neutrophil related diseases or conditions.

Abstract: The present disclosure relates to a supramolecular preparation of retinol and derivatives thereof and a preparation method therefor, wherein the supramolecular preparation consists of following components in percentage by mass: 3.00-25.0% of retinol and derivatives thereof, 36.5-91.0% of hydroxypropyl ?-cyclodextrin, 4.00-32.0% of hydroxypropyl methylcellulose stearoxy ether, and 2.00-8.0% of PEG/PPG/polybutylene glycol-8/5/3 glycerin, wherein the mass ratio of the PEG/PPG/polybutylene glycol-8/5/3 glycerin to the hydroxypropyl methylcellulose stearoxy ether is 1:2-4. The supramolecular preparation of retinol and derivatives thereof obtained in the present disclosure has the advantages such as good stability, high solubility, low irritation, and good anti-wrinkle effect.

Abstract: Systems, methods, and apparatuses for generating and releasing iodine are described. Some embodiments may include a dressing member including a plurality of iodine-forming reagents and a water-swellable material. In some embodiments, the dressing member may include water-swellable fibers. The water-swellable fibers may each include a water-swellable material in which iodine-forming reagents are dispersed. As liquid comes into contact with and is absorbed by the water-swellable material, the iodine-forming reagents may come into contact with each other, causing an iodine-forming reaction to occur, producing iodine.

Abstract: An insoluble transdermal microneedle patch, includes microneedles and a backing. The microneedles include bases and needlepoints located on the base, and materials made for the microneedles include crosslinked sodium alginate. The backing is connected with the bases, and parts of the backing corresponding to the needlepoints are hollow portions. The microneedle patch can act in the skin for a long time, during it is used for transdermal delivery, drugs can enter skin micropores to be absorbed into a body through pores formed after swelled microneedles acting on the skin absorbs water, thereby increasing a bioavailability of the drugs during the transdermal delivery. After drug administration end, the microneedles are completely removed without increasing a metabolic burden in the body, soluble materials are prevented from being accumulated in the body, and the microneedles have good biological safety. A preparation method of the insoluble transdermal microneedle patch and application thereof are provided.

Abstract: Symmetrically and asymmetrically branched homopolymers are modified at the surface level with functional groups that enable forming aggregates with a taxane, such as, paclitaxel and derivatives thereof, which are water insoluble or poorly water soluble. The aggregates are formed by interaction of a taxane and a homopolymer. Such aggregates improve drug solubility, stability, delivery and efficacy.

Abstract: Provided herein is a first fluid dispersed in a second fluid to form an emulsion of micro-droplets having an average droplet size and having a droplet size distribution around the average droplet size and below a maximum droplet size. The micro-droplets will lose their solvent to transform to micro-spheres exhibiting a particle size distribution around an average particle size and substantially below a maximum allowable particle size. The micro-spheres are subjected to a micro-filter having a relatively narrow pore size distribution around an average pore size, which average pore size is between the average particle size and the maximum particle size. A filtrate of the micro-filter comprises a majority of the micro-spheres that is substantially void of micro-spheres having a particle size exceeding the maximum allowable particle size.

Abstract: Provided are pharmaceutical compositions and methods for preparing pharmaceutical compositions using solventless mixing methods. Excess coating material that is not bound to a coated API particle may be removed by a sieving process. Coating and dosing ratios can also be optimized to minimize the amount of excess unbound coating material. Specifically, a coating ratio and/or a dosing ratio can be used to minimize the residual amount of excess unbound coating material to minimize agglomeration of coating material during storage. In some embodiments, a pharmaceutical composition is provided, the pharmaceutical composition comprising: 65-85% w/w API particles; 15-30% w/w coating material coating the API particles; and 3-15% w/w matrix surrounding the coated API particles, wherein the pharmaceutical composition comprises a disintegration time rate of less than 10 seconds for at least six months under storage conditions of at least 25° C. and at least 60% relative humidity.

Abstract: Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.

Abstract: This invention concerns a formulation of a hydrated mixed metal hydroxide and a nontoxic, non-anionic thickener, to form a salve or lotion which does cause synereses of the formulation. This formulation, when applied to a person or animal, forms a film that acts as an astringent, has antimicrobial palliative properties for many negative pathogens, burns, rashes and other skin maladies.

Abstract: Pharmaceutical formulation comprising centanafadine or a pharmaceutically acceptable salt thereof and an excipient, and related methods of manufacture and use, are disclosed.

Abstract: A biocompatible medical device is provided having at least one surface, wherein at least a part of this surface is coated with a biocompatible layer configured to provide visibility of the device in X-rays.

Abstract: The invention relates to supramolecular metal coordinated liothyronine (triiodothyronine, T3) compositions, methods of preparing such compositions, methods of purifying and formulating supramolecular metal coordinated liothyronine, and methods of treating hypothyroidism and other disease states using such compositions.

Abstract: Disclosed herein are embodiments of therapeutic substances that contain solid sodium percarbonate for use in a bath, and packaging for the therapeutic substances. The solid sodium percarbonate can be dissolved in a liquid, such as water, to produce a hydrogen peroxide solution. Hydrogen peroxide solutions can be provide beneficial effects to a user. The titrated sodium percarbonate can be mixed with other chemicals/materials in a pre-made packaging for ease of storage and using with a bath.

Abstract: A liquid pharmaceutical composition for intravenous administration that includes vasopressin or a pharmaceutically acceptable salt thereof. The formulation further includes a lactate buffer or lactic acid, optionally in combination with a pH adjuster. The pharmaceutical composition can have a pH of from about 3.0 to about 4.1 and demonstrates improved stability for long term storage, particularly at room temperature.

Abstract: The present invention relates to the field of coating pharmaceutical substrates. In particular, the invention relates to methods of coating of pharmaceutical substances, pharmaceutical ingredients or a blend of them. The invention also provides a method of making a pharmaceutical formulation which may be processed into a pharmaceutical dosage form, which utilizes solid pharmaceutical particles and a pharmaceutical formulation obtained by the method. The methods of the invention utilize atomic layer deposition technology. The novel methods allow difficult, moisture sensitive and electrically charged pharmaceutical substrates to be easily processable.

Abstract: The present disclosure relates to compositions useful in synthetic bone graft applications. Particularly, the disclosure teaches moldable bone graft compositions, methods of making the compositions, and methods of utilizing the same.

Abstract: Provided are solid oral/per os formulations that include a single cannabinoid, combination of cannabinoids, cannabis extract and combination of cannabis plant constituents. Also provided are methods of making the formulations, as well as therapeutic applications in the treatment and alleviation of various human disorders and/or conditions.